OST-HER2 is an immunotherapy for osteosarcoma using a HER2 bioengineered form of the bacteria Listeria monocytogenes to trigger a strong immune response against cancer cells expressing HER2.

Yet to be published data from clinical study combining OST-HER2 with palliative radiation in dogs with unresected, primary osteosarcoma shows clinical and radiographic arrest of the primary tumor ...

(RTTNews) - OS Therapies Inc. (OSTX) Thursday announced positive data for OST-HER2 in combination with palliative radiation in dogs with unresected appendicular osteosarcoma. Results from the ...